Role of the tumor immune microenvironment in tumor immunotherapy (Review)
- Authors:
- Changsheng Zhou
- Qianqian Liu
- Yi Xiang
- Xin Gou
- Wengang Li
-
Affiliations: Department of Hepatobiliary Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361102, P.R. China, Department of Hepatobiliary Surgery, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, P.R. China - Published online on: December 20, 2021 https://doi.org/10.3892/ol.2021.13171
- Article Number: 53
-
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Hao M, Hou S, Li W, Li K, Xue L, Hu Q, Zhu L, Chen Y, Sun H, Ju C and Zhang C: Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Sci Transl Med. 12:eaaz66672020. View Article : Google Scholar : PubMed/NCBI | |
Perets R, Bar J, Rasco DW, Ahn MJ, Yoh K, Kim DW, Nagrial A, Satouchi M, Lee DH, Spigel DR, et al: Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 32:395–403. 2021. View Article : Google Scholar : PubMed/NCBI | |
Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, et al: Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer. 18:9132018. View Article : Google Scholar : PubMed/NCBI | |
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al: The immune landscape of cancer. Immunity. 48:812–830.e14. 2018. View Article : Google Scholar : PubMed/NCBI | |
Eckstein M and Gupta S: New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: A never ending story? Ann Transl Med. 7 (Suppl 3):S1352019. View Article : Google Scholar : PubMed/NCBI | |
Beckermann KE, Dudzinski SO and Rathmell JC: Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev. 35:7–14. 2017. View Article : Google Scholar : PubMed/NCBI | |
Fukumura D, Kloepper J, Amoozgar Z, Duda DG and Jain RK: Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol. 15:325–340. 2018. View Article : Google Scholar : PubMed/NCBI | |
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ando M, Ito M, Srirat T, Kondo T and Yoshimura A: Memory T cell, exhaustion, and tumor immunity. Immunol Med. 43:1–9. 2020. View Article : Google Scholar : PubMed/NCBI | |
Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, et al: Author correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 20:15562019. View Article : Google Scholar : PubMed/NCBI | |
Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, et al: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 20:326–336. 2019. View Article : Google Scholar : PubMed/NCBI | |
He R, Hou S, Liu C, Zhang A, Bai Q, Han M, Yang Y, Wei G, Shen T, Yang X, et al: Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection. Nature. 537:412–428. 2016. View Article : Google Scholar : PubMed/NCBI | |
Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, et al: Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 537:417–421. 2016. View Article : Google Scholar : PubMed/NCBI | |
Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, Butler MO, Minden MD and Hirano N: A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 24:352–359. 2018. View Article : Google Scholar : PubMed/NCBI | |
Cho MK, Park JG, Iwata H and Kim EY: 2,3,7,8-Tetrachlorodibenzo-p-dioxin prompted differentiation to CD4+CD8−CD25+ and CD4+CD8+CD25+ Tregs and altered expression of immune-related genes in the thymus of chicken embryos. Ecotoxicol Environ Saf. 211:1119472021. View Article : Google Scholar : PubMed/NCBI | |
Pompura SL, Wagner A, Kitz A, LaPerche J, Yosef N, Dominguez-Villar M and Hafler DA: Oleic acid restores suppressive defects in tissue-resident FOXP3 Tregs from patients with multiple sclerosis. J Clin Invest. 131:e1385192021. View Article : Google Scholar : PubMed/NCBI | |
Shevyrev D and Tereshchenko V: Treg heterogeneity, function, and homeostasis. Front Immunol. 10:31002020. View Article : Google Scholar : PubMed/NCBI | |
Wherry EJ and Kurachi M: Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 15:486–499. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kurtulus S, Sakuishi K, Ngiow SF, Joller N, Tan DJ, Teng MW, Smyth MJ, Kuchroo VK and Anderson AC: TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 125:4053–4062. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zarour HM: Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res. 22:1856–1864. 2016. View Article : Google Scholar : PubMed/NCBI | |
Yuen GJ, Demissie E and Pillai S: B lymphocytes and cancer: A love-hate relationship. Trends Cancer. 2:747–757. 2016. View Article : Google Scholar : PubMed/NCBI | |
van de Veen W, Globinska A, Jansen K, Straumann A, Kubo T, Verschoor D, Wirz OF, Castro-Giner F, Tan G, Rückert B, et al: A novel proangiogenic B cell subset is increased in cancer and chronic inflammation. Sci Adv. 6:eaaz35592020. View Article : Google Scholar : PubMed/NCBI | |
Ni Z, Xing D, Zhang T, Ding N, Xiang D, Zhao Z, Qu J, Hu C, Shen X, Xue X and Zhou J: Tumor-infiltrating B cell is associated with the control of progression of gastric cancer. Immunol Res. 69:43–52. 2020. View Article : Google Scholar : PubMed/NCBI | |
Satoh M, Takano S, Sogawa K, Noda K, Yoshitomi H, Ishibashi M, Mogushi K, Takizawa H, Otsuka M, Shimizu H, et al: Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer. Cancer Sci. 108:795–803. 2017. View Article : Google Scholar : PubMed/NCBI | |
Nakamura K and Smyth MJ: Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 17:1–12. 2020. View Article : Google Scholar : PubMed/NCBI | |
Rubio AJ, Porter T and Zhong X: Duality of B Cell-CXCL13 axis in tumor immunology. Front Immunol. 11:5211102020. View Article : Google Scholar : PubMed/NCBI | |
Ou Z, Wang Y, Liu L, Li L, Yeh S, Qi L and Chang C: Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals. Oncotarget. 6:26065–26078. 2015. View Article : Google Scholar : PubMed/NCBI | |
Bodogai M, Moritoh K, Lee-Chang C, Hollander CM, Sherman-Baust CA, Wersto RP, Araki Y, Miyoshi I, Yang L, Trinchieri G and Biragyn A: Immunosuppressive and prometastatic functions of myeloid-derived suppressive cells rely upon education from tumor-associated B cells. Cancer Res. 75:3456–3465. 2015. View Article : Google Scholar : PubMed/NCBI | |
Tabuchi Y, Shimoda M, Kagara N, Naoi Y, Tanei T, Shimomura A, Shimazu K, Kim SJ and Noguchi S: Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer. Breast Cancer Res Treat. 157:55–63. 2016. View Article : Google Scholar : PubMed/NCBI | |
Rossetti RAM, Lorenzi NPC, Yokochi K, Rosa MBSF, Benevides L, Margarido PFR, Baracat EC, Carvalho JP, Villa LL and Lepique AP: B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses. PLoS One. 13:e01990342018. View Article : Google Scholar : PubMed/NCBI | |
Bald T, Krummel MF, Smyth MJ and Barry KC: The NK cell-cancer cycle: Advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 21:835–847. 2020. View Article : Google Scholar : PubMed/NCBI | |
Tarazona R, Lopez-Sejas N, Guerrero B, Hassouneh F, Valhondo I, Pera A, Sanchez-Correa B, Pastor N, Duran E, Alonso C and Solana R: Current progress in NK cell biology and NK cell-based cancer immunotherapy. Cancer Immunol Immunother. 69:879–899. 2020. View Article : Google Scholar : PubMed/NCBI | |
Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, Moretta F, Ingegnere T, Mingari MC, Moretta A and Moretta L: Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom. 92:100–114. 2017. View Article : Google Scholar : PubMed/NCBI | |
Handgretinger R, Lang P and André MC: Exploitation of natural killer cells for the treatment of acute leukemia. Blood. 127:3341–3349. 2016. View Article : Google Scholar : PubMed/NCBI | |
Myers JA and Miller JS: Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 18:85–100. 2021. View Article : Google Scholar : PubMed/NCBI | |
Kim N and Kim HS: Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells. Front Immunol. 9:20412018. View Article : Google Scholar : PubMed/NCBI | |
Minetto P, Guolo F, Pesce S, Greppi M, Obino V, Ferretti E, Sivori S, Genova C, Lemoli RM and Marcenaro E: Harnessing NK cells for cancer treatment. Front Immunol. 10:28362019. View Article : Google Scholar : PubMed/NCBI | |
Tinker AV, Hirte HW, Provencher D, Butler M, Ritter H, Tu D, Azim HA Jr, Paralejas P, Grenier N, Hahn SA, et al: Dose-ranging and cohort-expansion study of monalizumab (IPH2201) in patients with advanced gynecologic malignancies: A Trial of the Canadian cancer trials group (CCTG): IND221. Clin Cancer Res. 25:6052–6060. 2019. View Article : Google Scholar : PubMed/NCBI | |
Metes D, Galatiuc C, Moldovan I, Morel PA, Chambers WH, DeLeo AB, Rabinowich H, Schall R, Whiteside TL, Sulica A, et al: Expression and function of Fc gamma RII on human natural killer cells. Nat Immun. 13:289–300. 1994.PubMed/NCBI | |
Braud VM, Allan DS, O'Callaghan CA, Söderström K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, et al: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 391:795–799. 1998. View Article : Google Scholar : PubMed/NCBI | |
Grossenbacher SK, Canter RJ and Murphy WJ: Natural killer cell immunotherapy to target stem-like tumor cells. J Immunother Cancer. 4:192016. View Article : Google Scholar : PubMed/NCBI | |
Imai K, Matsuyama S, Miyake S, Suga K and Nakachi K: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet. 356:1795–1799. 2000. View Article : Google Scholar : PubMed/NCBI | |
Lupo KB and Matosevic S: Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy. Cancers (Basel). 11:7692019. View Article : Google Scholar : PubMed/NCBI | |
Al-Attar A, Presnell SR, Clasey JL, Long DE, Walton RG, Sexton M, Starr ME, Kern PA, Peterson CA and Lutz CT: human body composition and immunity: Visceral adipose tissue produces IL-15 and muscle strength inversely correlates with NK Cell function in elderly humans. Front Immunol. 9:4402018. View Article : Google Scholar : PubMed/NCBI | |
Wang LX, Tong X, Li C, Giddens JP and Li T: Glycoengineering of antibodies for modulating functions. Annu Rev Biochem. 88:433–459. 2019. View Article : Google Scholar : PubMed/NCBI | |
Baba Y, Nomoto D, Okadome K, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N and Baba H: Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 111:3132–3141. 2020. View Article : Google Scholar : PubMed/NCBI | |
Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, Wang P, Su X, Qin Y, Wang Y, et al: Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther. 6:262021. View Article : Google Scholar : PubMed/NCBI | |
Teng CF, Wang T, Shih FY, Shyu WC and Jeng LB: Therapeutic efficacy of dendritic cell vaccine combined with programmed death 1 inhibitor for hepatocellular carcinoma. J Gastroenterol Hepatol. 36:1988–1996. 2021. View Article : Google Scholar : PubMed/NCBI | |
Jia Y, Liu L and Shan B: Future of immune checkpoint inhibitors: Focus on tumor immune microenvironment. Ann Transl Med. 8:10952020. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Song Y, Du W, Gong L, Chang H and Zou Z: Tumor-associated macrophages: An accomplice in solid tumor progression. J Biomed Sci. 26:782019. View Article : Google Scholar : PubMed/NCBI | |
Hwang I, Kim JW, Ylaya K, Chung EJ, Kitano H, Perry C, Hanaoka J, Fukuoka J, Chung JY and Hewitt SM: Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients. J Transl Med. 18:4432020. View Article : Google Scholar : PubMed/NCBI | |
Han S, Wang W, Wang S, Yang T, Zhang G, Wang D, Ju R, Lu Y, Wang H and Wang L: Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes. Theranostics. 11:2892–2916. 2021. View Article : Google Scholar : PubMed/NCBI | |
Shan H, Dou W, Zhang Y and Qi M: Targeted ferritin nanoparticle encapsulating CpG oligodeoxynucleotides induces tumor-associated macrophage M2 phenotype polarization into M1 phenotype and inhibits tumor growth. Nanoscale. 12:22268–22280. 2020. View Article : Google Scholar : PubMed/NCBI | |
Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, Sirven P, Magagna I, Fuhrmann L, Bernard C, et al: Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 33:463–479.e10. 2018. View Article : Google Scholar : PubMed/NCBI | |
De Jaeghere EA, Denys HG and De Wever O: Fibroblasts fuel immune escape in the tumor microenvironment. Trends Cancer. 5:704–723. 2019. View Article : Google Scholar : PubMed/NCBI | |
Maia A, Gu Z, Koch A, Berdiel-Acer M, Will R, Schlesner M and Wiemann S: IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment. Mol Oncol. 15:1308–1329. 2021. View Article : Google Scholar : PubMed/NCBI | |
Shi Y, Sun L, Zhang R, Hu Y, Wu Y, Dong X, Dong D, Chen C, Geng Z, Li E and Fan Y: Thrombospondin 4/integrin α2/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells. J Exp Clin Cancer Res. 40:142021. View Article : Google Scholar : PubMed/NCBI | |
Zhou L, Li J, Tang Y and Yang M: Exosomal LncRNA LINC00659 transferred from cancer-associated fibroblasts promotes colorectal cancer cell progression via miR-342-3p/ANXA2 axis. J Transl Med. 19:82021. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Liu Z, Yang X, Lu W, Chen Y, Lin Y, Wang J, Lin S and Yun JP: H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts. Theranostics. 11:1473–1492. 2021. View Article : Google Scholar : PubMed/NCBI | |
Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, Gao Y and Li K: Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 11:3092020. View Article : Google Scholar : PubMed/NCBI | |
Liu Y, Zhou N, Zhou L, Wang J, Zhou Y, Zhang T, Fang Y, Deng J, Gao Y, Liang X, et al: IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor. Nat Immunol. 22:358–369. 2021. View Article : Google Scholar : PubMed/NCBI | |
Sahin D, Arenas-Ramirez N, Rath M, Karakus U, Hümbelin M, van Gogh M, Borsig L and Boyman O: An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer. Nat Commun. 11:64402020. View Article : Google Scholar : PubMed/NCBI | |
Renavikar PS, Sinha S, Brate AA, Borcherding N, Crawford MP, Steward-Tharp SM and Karandikar NJ: IL-12-induced immune suppressive deficit during CD8+ T-cell differentiation. Front Immunol. 11:5686302020. View Article : Google Scholar : PubMed/NCBI | |
Tucker CG, Mitchell JS, Martinov T, Burbach BJ, Beura LK, Wilson JC, Dwyer AJ, Singh LM, Mescher MF and Fife BT: Adoptive T Cell Therapy with IL-12-preconditioned low-avidity T cells prevents exhaustion and results in enhanced T cell activation, enhanced tumor clearance, and decreased risk for autoimmunity. J Immunol. 205:1449–1460. 2020. View Article : Google Scholar : PubMed/NCBI | |
Agliardi G, Liuzzi AR, Hotblack A, De Feo D, Núñez N, Stowe CL, Friebel E, Nannini F, Rindlisbacher L, Roberts TA, et al: Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 12:4442021. View Article : Google Scholar : PubMed/NCBI | |
Jiang X, Ren L, Tebon P, Wang C, Zhou X, Qu M, Zhu J, Ling H, Zhang S, Xue Y, et al: Cancer-on-a-chip for modeling immune checkpoint inhibitor and tumor interactions. Small. 17:e20042822021. View Article : Google Scholar : PubMed/NCBI | |
Duchemann B, Pluvy J, Crestani B, Zalcman G and Nunes H: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. Eur J Cancer. 145:179–182. 2021. View Article : Google Scholar : PubMed/NCBI | |
Ceresoli GL and Pasello G: Immune checkpoint inhibitors in mesothelioma: A turning point. Lancet. 397:348–349. 2021. View Article : Google Scholar : PubMed/NCBI | |
Wakita A, Motoyama S, Nanjo H, Sato Y, Yoshino K, Sasaki T, Kawakita Y, Liu J, Imai K, Saito H and Minamiya Y: PD-L1 expression is a prognostic factor in patients with thoracic esophageal cancer treated without adjuvant chemotherapy. Anticancer Res. 37:1433–1441. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yoshida H, Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Ajimizu H, Yamazoe M, Kuninaga K, Ogimoto T, et al: PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade. Eur J Cancer. 144:317–325. 2021. View Article : Google Scholar : PubMed/NCBI | |
Tan CL, Kuchroo JR, Sage PT, Liang D, Francisco LM, Buck J, Thaker YR, Zhang Q, McArdel SL, Juneja VR, et al: PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J Exp Med. 218:e201822322021. View Article : Google Scholar : PubMed/NCBI | |
Liotti F, Kumar N, Prevete N, Marotta M, Sorriento D, Ieranò C, Ronchi A, Marino FZ, Moretti S, Colella R, et al: PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. J Exp Clin Cancer Res. 40:222021. View Article : Google Scholar : PubMed/NCBI | |
Marcq E, Van Audenaerde JRM, De Waele J, Merlin C, Pauwels P, van Meerbeeck JP, Fisher SA and Smits ELJ: The search for an interesting partner to combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3. Cancers (Basel). 13:2822021. View Article : Google Scholar : PubMed/NCBI | |
Yang M, Lu J, Zhang G, Wang Y, He M, Xu Q, Xu C and Liu H: CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J Immunother Cancer. 9:e0011362021. View Article : Google Scholar : PubMed/NCBI | |
Dovedi SJ, Elder MJ, Yang C, Sitnikova SI, Irving L, Hansen A, Hair J, Jones DC, Hasani S, Wang B, et al: Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells. Cancer Discov. 11:1100–1117. 2021. View Article : Google Scholar : PubMed/NCBI | |
Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, et al: Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 38:4138–4148. 2020. View Article : Google Scholar : PubMed/NCBI | |
Lecocq Q, Keyaerts M, Devoogdt N and Breckpot K: The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: Third time's a charm. Int J Mol Sci. 22:752020. View Article : Google Scholar : PubMed/NCBI | |
Atkinson V, Khattak A, Haydon A, Eastgate M, Roy A, Prithviraj P, Mueller C, Brignone C and Triebel F: Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. J Immunother Cancer. 8:e0016812020. View Article : Google Scholar : PubMed/NCBI | |
Harjunpää H and Guillerey C: TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 200:108–119. 2020. View Article : Google Scholar : PubMed/NCBI | |
Judge SJ, Darrow MA, Thorpe SW, Gingrich AA, O'Donnell EF, Bellini AR, Sturgill IR, Vick LV, Dunai C, Stoffel KM, et al: Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. J Immunother Cancer. 8:e0013552020. View Article : Google Scholar : PubMed/NCBI | |
Han HS, Jeong S, Kim H, Kim HD, Kim AR, Kwon M, Park SH, Woo CG, Kim HK, Lee KH, et al: TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. Cancer Lett. 499:137–147. 2021. View Article : Google Scholar : PubMed/NCBI | |
Li W, Deng C, Yang H, Lu X, Li S, Liu X, Chen F, Chen L, Shu X, Zhang L, et al: Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis. Arthritis Res Ther. 23:152021. View Article : Google Scholar : PubMed/NCBI | |
Han JH, Cai M, Grein J, Perera S, Wang H, Bigler M, Ueda R, Rosahl TW, Pinheiro E, LaFace D, et al: Effective Anti-tumor response by TIGIT blockade associated with FcγR Engagement and myeloid cell activation. Front Immunol. 11:5734052020. View Article : Google Scholar : PubMed/NCBI | |
Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, et al: PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. J Immunother Cancer. 8:e0016312020. View Article : Google Scholar : PubMed/NCBI |